Ankylosing Spondylitis
ConditionAnkylosing Spondylitis
Trial statusNot yet recruiting
Trial phaseNot listed
Trial typeObservational
Biological sexAll
Age16-80
SponsorSohag University
About this trial
The goal of this observational study is to measure the serum level of cytokines IL-17, IL-38,IL-41, and gene expression of HLA-B27 gene in ankylosing spondylitis patients and healthy control group.
The main question it aims to answer is:
Does the disease activity, severity, serum level of cytokines (IL-17, IL-38, and IL-41) are affected by the HLA-b27 gene positivity?
Researchers will compare the serum level of cytokines IL-17, IL-38,IL-41, and gene expression of HLA-B27 gene in ankylosing spondylitis patients and healthy control group to see if there significant differences in serum levels of interleukins 17, 38, 41 in AS patients and healthy control group.
.
Eligibility criteria
Qualifiers
patients who are diagnosed clinically as ankylosing spondylitis (both active or stable), of either sex , who met the Assessment of Spondyloarthritis International Society (ASAS) criteria for axial spondyloarthritis.
Disqualifiers
Patients with any autoimmune disorder, chronic illnesses as diabetes mellitus, acute and chronic infectious diseases, malignancy.
Trial design
Treatments tested in this trial
- Not listed
Trial groups
84 Participants
are grouped into 2 trial groupsLocations
Sponsors and collaborators
Source ClinicalTrials.gov